These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37078149)

  • 1. Adoption of sodium-glucose cotransporter-2 inhibitors among prescribers caring for nursing home residents.
    Hayes KN; Berry SD; Munshi MN; Zullo AR
    J Am Geriatr Soc; 2023 Aug; 71(8):2585-2592. PubMed ID: 37078149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.
    Sangha V; Lipska K; Lin Z; Inzucchi SE; McGuire DK; Krumholz HM; Khera R
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008381. PubMed ID: 34779654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults.
    Zullo AR; Smith RJ; Gutman R; Kohler B; Duprey MS; Berry SD; Munshi MN; Dore DD
    J Am Geriatr Soc; 2021 Oct; 69(10):2923-2930. PubMed ID: 34291453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.
    Zaghloul N; Awaisu A; Mahfouz A; Alyafei S; Elewa H
    Int J Clin Pharm; 2022 Dec; 44(6):1342-1350. PubMed ID: 36169802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic Prescribing Patterns for Urinary Tract Infections and Pneumonia by Prescriber Type and Specialty in Nursing Home Care, 2016-2018.
    Silva JBB; Riester MR; Zullo AR
    J Am Med Dir Assoc; 2024 May; 25(5):769-773.e9. PubMed ID: 38428833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
    Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
    [No Abstract]   [Full Text] [Related]  

  • 8. Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011.
    Lee SJ; Stijacic-Cenzer I; Barnhart C; McClymont K; Steinman MA
    J Am Med Dir Assoc; 2015 Oct; 16(10):898.e9-14. PubMed ID: 26272298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents.
    Zhang T; Zullo AR; Hayes KKN; Kim DH; Lee Y; Daiello LA; Kiel DP; Berry SD
    J Am Med Dir Assoc; 2024 Mar; 25(3):454-458. PubMed ID: 37553080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
    Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
    BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in add-on medications following metformin monotherapy for type 2 diabetes.
    Swart EC; Neilson LM; Munshi KD; Peasah SK; Henderson R; Good CB
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1253-1259. PubMed ID: 36282929
    [No Abstract]   [Full Text] [Related]  

  • 12. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus.
    Lapane KL; Jesdale BM; Dubé CE; Pimentel CB; Rajpathak SN
    Diabetes Res Clin Pract; 2015 Aug; 109(2):411-9. PubMed ID: 26008723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents.
    Zullo AR; Dore DD; Gutman R; Mor V; Alvarez CA; Smith RJ
    J Am Med Dir Assoc; 2017 Oct; 18(10):879-884.e7. PubMed ID: 28676291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States.
    Zhao JZ; Weinhandl ED; Carlson AM; St Peter WL
    Kidney Med; 2022 Aug; 4(8):100510. PubMed ID: 35898692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis.
    Yang L; Gabriel N; Bian J; Bilello LA; Wright DR; Hernandez I; Guo J
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1242-1251. PubMed ID: 37889868
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.
    Wisniewski B; Smith E; Kaur J; Sherling C; Vanapalli S; Lussier M
    J Manag Care Spec Pharm; 2024 Jan; 30(1):34-42. PubMed ID: 38153863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.